May 7 |
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
|
May 6 |
BioAtla announces FDA clearance of ind application for its treatment of multiple tumors
|
May 6 |
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
|
May 2 |
BioAtla: A Buried ADC Concern Gets Some New Life In 2024
|
Apr 24 |
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Mar 28 |
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
|
Mar 27 |
BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript
|
Mar 27 |
Q4 2023 Bioatla Inc Earnings Call
|
Mar 26 |
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
|
Mar 26 |
BioAtla: Q4 Earnings Insights
|